Weekly Research Analysts’ Ratings Changes for Enliven Therapeutics (ELVN)

Several brokerages have updated their recommendations and price targets on shares of Enliven Therapeutics (NASDAQ: ELVN) in the last few weeks:

• 8/18/2026 – Enliven Therapeutics is now covered by William Blair. They set an “outperform” rating on the stock.
• 8/18/2026 – Enliven Therapeutics is now covered by Barclays PLC. They set an “overweight” rating and a $78.00 price target on the stock.
• 8/18/2026 – Enliven Therapeutics had its price target raised by Mizuho from $62.00 to $73.00. They now have an “outperform” rating on the stock.
• 8/8/2026 – Enliven Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/6/2026 – Enliven Therapeutics had its price target lowered by Guggenheim from $80.00 to $78.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Enliven Therapeutics had its price target raised by Stifel Nicolaus from $80.00 to $82.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Enliven Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $67.00 to $80.00. They now have a “buy” rating on the stock.
• 7/21/2026 – Enliven Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $59.00 to $67.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Enliven Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/9/2026 – Enliven Therapeutics had its price target raised by HC Wainwright from $56.00 to $64.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Enliven Therapeutics had its price target raised by Stifel Nicolaus from $60.00 to $80.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Enliven Therapeutics had its price target raised by JonesTrading from $45.00 to $70.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other Enliven Therapeutics news, Director Mika K. Derynck sold 158,795 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director directly owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the transaction, the chief financial officer owned 40,036 shares of the company’s stock, valued at $2,345,308.88. This trade represents a 13.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 196,849 shares of company stock valued at $11,344,257. Company insiders own 3.00% of the company’s stock.

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.